After digging into 100+ startups on Crunchbase.com for fun, here are the startups (which I fervently believe) are on the path to become Unicorns–>The table below:
The reasoning behind my selections are:
1.They are all ‘must-have’ companies, not ‘good-to-have’ companies. Therefore, irreplaceability.
2. Market size (+ their ability to create new market)
3. Timing & urgency for their products
4. Management (Particularly strong tech leads and experts for each specialization)
They are all ‘must-have’ companies, not ‘good-to-have’ companies. Therefore, they will become Unicorns extremely faster than companies inflated by whatsoever ‘popular terms’.
| Name | What does they do | Location | Investors | Note |
| Cleerly | Digital healthcare company that offers heart disease diagnosis | US | Peter Thiel | Founded in 2017 by James K.Min. He has raised a total of $280.5m in funding over 3 rounds |
| Idrx | A clinical stage biopharmaceutical company dedicated to transforming cancer treatment | US | Andreessen Horowitz | |
| Relativity | Manage large volumes of data and identify key issues during litigation, investigations, and compliance | US | Silver Lake | Simply powerful software for legal& compliance |
| Arena | Empowers businesses across industries to make high frequency decisions fully autonomous | New York, US | Peter Thiel, Founders Fund | Has raised a total of $32m in Aug 2, 2022 |
| Zuora | Provides cloud-based software on a subscription basis that helps companies launch, manage, and transform into a subscription business | US | Silver Lake, Index Ventures, BlackRock, Marc Benioff | $647.5m total funding amount |
| Constructive Bio | Creating artificial genomes and rewriting the genetic code of living things | UK | – | $15m total funding amount |
| Replay | A genome writing company reprogramming biology by writing and delivering big DNA | US | KKR | |
| Senzo | Developed a lateral flow test which delivers the same accuracy as lab-based PCR, with results available within 10 minutes. This can be used to test the most prevalent diseases, Flu A/B, Covid-19, Tuberculosis, Hepatitis C, HIV, C.difficile | US | – | Total funding amount $2m |
| Produze | Enables agricultural farmers to sell directly to worldwide merchants, providing them with consistent quality and reasonable pricing | India | Accel | |
| Trumid | A financial tech company and fixed income electronic trading platform | New York, US | BlackRock | |
| Ghost | Building self driving platform for a new generation of consumer cars | California, US | Founders Fund, Khosla Ventures | |
| Persephone Biosciences | Uses AI to rapidly develop microbial based immunotherapies to enable a lifetime without cancer | US | Y Combinator, ZhenFund | |
| Paper Cup | Translating videos using AI by generating voices that sound like the original speaker | London, UK | Octopus Ventures | |
| Do Not Pay | Fight corporation bureaucracy, and sue anyone at the press of a button. Online robot lawyer that allows people to automatically claim asylum in the US, UK, and Canada for free | US | Andreessen Horowitz, Index Ventures, Founders Fund | |
| Passionfruit | Freelancing platform for Gen Z marketers | London, UK | ||
| Halliday | Buy gaming and Metaverse NFTs and start using them right away | US | Andreessen Horowitz | |
| Appsilon Enterprise B.V | Deep tech that grows diamond in the lab | Delft, The Netherlands | ||
| Qdama | A fresh agricultural product service provider that focuses on the operation of the fresh meat market | Guangdong, China | ||
| CreatorSpace | Facilitates the connection between ambitious creators and supports them in starting amazing new projects and companies | Zurich, Switzerland | ||
| Pulley | Offers a cap table management platform designed to help startup founders, employees, and investors monitor their equity information | US | Founders Fund, Y Combinator | |
| Alloy Therapeutics | A biotechnology ecosystem company that offers technologies to the entire drug discovery community. It makes foundational drug discovery capabilities and technologies available to all | US | Peter Thiel | |
| Monte Carlo | A digital data reliability platform designed to monitor and offer alerts for missing or inaccurate data | US | GGV Capital, Accel |
Cleerly
James Min
Founder/CEO
James K. Min, MD is a former Professor of Radiology and Medicine at Weill Cornell Medical College and the Director of the Dalio Institute of Cardiovascular Imaging (ICI) at NewYork-Presbyterian. He is a board-certified cardiologist with a clinical focus on cardiovascular disease prevention and cardiovascular imaging.
Cleerly is redefining cardiovascular care by leveraging new technologies to help physicians better identify at-risk patients and provide the most effective preventive and precision heart care.
AI-driven CCTA analysis enables early heart disease detection.
Coronary phenotyping supports personalized analysis and treatment.
Funding rounds:
Cleerly has raised a total of $280.5M in funding over 3 rounds. Their latest funding was raised on Jul 25, 2022 from a Series C round.
Investors: Peter Thiel, Fidelity Management
Arena
Pratap Ranade
Co-founder/CEO
Pratap brings 11 years of experience building companies, products and teams that specialize in engineering and machine learning.
Most recently, Pratap led Engineering & Machine Learning at Enigma, where he re-built the engineering team, growing it to 75. Beyond engineering, he created and launched a new flagship product.
Arena’s products have helped some of the world’s largest consumer-goods companies transform their sales and supply chains into autonomous, self-learning systems — unlocking massive efficiencies and resulting in a better, more affordable consumer experience.
But autonomous selling is just the beginning. Autonomous systems can tackle much more. They can help supply chains run more efficiently to deliver critical goods and services more affordably, sustainably and equitably to the world; they can help renewable energy providers reduce green premiums and compete more effectively with fossil fuels; and they can help make microchips safer and more abundant by automating painstaking testing and validation processes that hold back the world’s most critical infrastructure.
Funding rounds:
Arena has raised a total of $32M in funding over 1 round. This was a Series A round raised on Aug 2, 2022
Investors: Founders Fund, Peter Thiel
Persephone Biosciences
Stephanie Culler
Co-founder/CEO
Stephanie Culler, PhD, is the cofounder and CEO of Persephone Biosciences. She is a graduate of the prestigious Y Combinator accelerator. She received her PhD in chemical engineering from the California Institute of Technology under the mentorship of Christina Smolke and has numerous publications and patents on synthetic biology and microbial-based technologies.
Persephone Biosciences uses artificial intelligence to rapidly develop microbial based immunotherapies to enable a lifetime without cancer.
Funding rounds:
Persephone Biosciences has raised a total of $15.1m in funding over 4 rounds. Their latest funding was raised on Jul 19, 2022 from a Seed round
Investors: Y-Combinator, ZhenFund
The GillPower 